TimothyFBurnsMDPhD

PubMed

• TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer.
  Vinod Kumar, Zachary A Yochum, Princey Devadassan, Eric H-B Huang, Ethan Miller, Roja Baruwal, Purva H Rumde, Autumn L GaitherDavis, Laura P Stabile, Timothy F Burns> ;Oncogene. 2024 Mar 1
• p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer.
  Chatterjee, S., Wang, N., Huang, E., Yassin-Kassab, A., Khan, N., Sandulache, V., Burns, T., Duvvuri, U.> ;BMC Cancer. 2024 Feb 19
• Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution.
  Jaime L Schneider, Khvaramze Shaverdashvili, Mari Mino-Kenudson, Subba R Digumarthy, Andrew Do, Audrey Liu, Justin F Gainor, Jochen K Lennerz, Timothy F Burns, Jessica...> ;NPJ Precision Oncology. 2023 Nov 3
• Male sex and pretreatment weight loss are associated with poor outcome in patients with advanced non-small cell lung cancer treated with immunotherapy: a retrospective...
  Jingxiao Jin, Jacqueline Visina, Timothy F Burns, Brenda Diergaarde, Laura P Stabile> ;Scientific Reports. 2023 Oct 9
• Targeting the epidermal growth factor receptor following complete surgical resection in patients with early-stage non-small cell lung cancer.
  Khvaramze Shaverdashvili, Timothy F Burns> ;Expert Opinion on Pharmacotherapy. 2023 May 27
• 4 citations
  A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lu...
  Byoung Chul Cho, Sarah B Goldberg, Dong-Wan Kim, Mark A Socinski, Timothy F Burns, Zarnie Lwin, Nuzhat Pathan, Wei Dong Ma, Joanna C Masters, Nandini Cossons, Keith Wi...> ;Expert Opinion on Investigational Drugs. 2022 Jul 1
• 7 citations
  Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
  Richard S P Huang, Lukas Harries, Brennan Decker, Matthew C Hiemenz, Karthikeyan Murugesan, James Creeden, Khaled Tolba, Laura P Stabile, Shakti H Ramkissoon, Timothy ...> ;The Oncologist. 2022 Oct 1
• 19 citations
  A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC
  Christine L. Hann, Timothy F. Burns, Afshin Dowlati, Daniel Morgensztern, Patrick J. Ward, Martina M. Koch, Chris Chen, Carrianne Ludwig, Maulik Patel, Halla Nimeiri, ...> ;Journal of Thoracic Oncology. 2021 Jul 6
• 12 citations
  Syngeneic tobacco carcinogen-induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden.
  Laura P. Stabile, Vinod Kumar, Autumn Gaither-Davis, Eric H.-B. Huang, Frank P. Vendetti, Princey Devadassan, Sanja Dacic, Riyue Bao, Richard A. Steinman, Timothy F. B...> ;JCI Insight. 2021 Feb 8
• 23 citations
  Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.
  Timothy F. Burns, Hossein Borghaei, Suresh S. Ramalingam, Tony Mok, Solange Peters> ;Journal of Clinical Oncology. 2020 Oct 26
• 585 citations
  KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;The New England Journal of Medicine. 2020 Sep 20
• 42 citations
  HSP90 inhibitors in lung cancer: promise still unfulfilled.
  Suman Chatterjee, Saveri Bhattacharya, Mark A. Socinski, Timothy F. Burns> ;Clinical Advances in Hematology & Oncology. 2016 May 1
• 5 citations
  Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group.
  Patrick M. Forde, P. Bonomi, Alice T. Shaw, Gideon M. Blumenthal, Andrea Ferris, Chirag Patel, Allen S. Melemed, Upal Basu Roy, Anuradha Ramamoorthy, Qi Liu, Timothy F...> ;Clinical Lung Cancer. 2020 Feb 26
• 74 citations
  Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
  David E. Gerber, D. Ross Camidge, Daniel Morgensztern, Jeremey Cetnar, Ronan J. Kelly, Suresh S. Ramalingam, David R. Spigel, Woondong Jeong, Pier Paolo Scaglioni, Son...> ;Lung Cancer. 2020 Jan 1
• 7 citations
  The estrogen pathway as a modulator of response to immunotherapy.
  Maria A. Velez, Timothy F. Burns, Laura P. Stabile> ;Immunotherapy. 2019 Jul 30
• 11 citations
  Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?
  Maria A. Velez, Timothy F. Burns> ;Translational Lung Cancer Research. 2019 Apr 29
• 8 citations
  SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma
  Emily A. Bossart, Nilgun Tasdemir, Matthew J. Sikora, Amir Bahreini, Kevin M. Levine, Jian Chen, Ahmed Basudan, Britta M. Jacobsen, Timothy F. Burns, Steffi Oesterreich> ;Breast Cancer Research and Treatment. 2019 Feb 23
• 121 citations
  Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
  Zachary A. Yochum, Jessica Cades, Hailun Wang, Suman Chatterjee, Brian W. Simons, James P. O’Brien, Susheel K. Khetarpal, Ghali Lemtiri-Chlieh, Kayla V. Myers, Eric H....> ;Oncogene. 2019 Jan 1
• 2 citations
  TWIST1 regulation of circRNA: a novel mechanism to promote epithelial-mesenchymal transition in hepatocellular carcinoma
  Zachary A. Yochum, Timothy F. Burns> ;Non-Coding RNA Investigation. 2018 Dec 19
• 40 citations
  Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease - analysis of institutional and population data.
  Joo Heung Yoon, Mehdi Nouraie, X. Chen, Richard H. Zou, Jacobo Sellares, Kristen L. Veraldi, Jared Chiarchiaro, Kathleen O. Lindell, David O. Wilson, Naftali Kaminski,...> ;Respiratory Research. 2018 Oct 3
• 1 citations
  Cytogenetically cryptic insertion of PML segment into RARA on chromosome 17q resulting PML-RARA fusion in acute promyelocytic leukemia.
  Timothy F. Burns, Eric Y. Loo, Elizabeth M. Bengtson, Liming Bao> ;Annals of Hematology. 2019 Jan 1
• 16 citations
  HSP90 inhibition targets autophagy and induces a CASP9-dependent resistance mechanism in NSCLC.
  Jie Han, Leslie A. Goldstein, Wen Hou, Suman Chatterjee, Timothy F. Burns, Hannah Rabinowich> ;Autophagy. 2018 Mar 21
• 13 citations
  First-Line Osimertinib in Patients with Treatment-Naive Somatic or Germline EGFR T790M–Mutant Metastatic NSCLC
  Katerina Ancevski Hunter, David M. Friedland, Liza C. Villaruz, Timothy F. Burns> ;Journal of Thoracic Oncology. 2018 Jan 1
• 29 citations
  Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence
  Daniela Volonte, Avani R. Vyas, Chen Chen, Sanja Dacic, Laura P. Stabile, Brenda F. Kurland, Shira Abberbock, Timothy F. Burns, James G. Herman, Yuanpu Peter Di, Ferru...> ;The Journal of Biological Chemistry. 2017 Dec 15
• 51 citations
  A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer
  Zachary A. Yochum, Jessica Cades, Lucia Mazzacurati, Neil M. Neumann, Susheel K. Khetarpal, Suman Chatterjee, Hailun Wang, Myriam A. Attar, Eric H.-B. Huang, Sarah N. ...> ;Molecular Cancer Research. 2017 Dec 1
• Join now to see all